(secondQuint)Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy.

 The drug being tested in this study is called pioglitazone.

 Pioglitazone is being tested to treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus.

 This study will look at glycemic control in people who take triple oral therapy of metformin, sulfonylurea, and pioglitazone 15 mg.

 The study will enroll approximately 114 patients.

 All participants will be asked to take one pioglitazone tablet at the same time each day throughout the study as well as continuing their previous dose of metformin and sulfonylurea.

.

 This multi-centre trial will be conducted in Korea.

 The overall time to participate in this study is up to 25 weeks.

 Participants will make 4 visits to the hospital or endocrinologist's office, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment.

.

 Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy@highlight

The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control as when used in patients with inadequately controlled type 2 diabetes mellitus treated with fixed combinations of metformin and sulfonylurea.

